Duncker Streett & Co. Inc. raised its stake in Novartis AG (NYSE:NVS) by 17.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,565 shares of the company’s stock after buying an additional 1,415 shares during the period. Duncker Streett & Co. Inc.’s holdings in Novartis AG were worth $798,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. City Holding Co. raised its stake in shares of Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after buying an additional 54 shares during the last quarter. Howe & Rusling Inc. raised its stake in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock valued at $100,000 after buying an additional 882 shares during the last quarter. TCI Wealth Advisors Inc. raised its stake in shares of Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock valued at $103,000 after buying an additional 230 shares during the last quarter. Archford Capital Strategies LLC raised its stake in shares of Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after buying an additional 621 shares during the last quarter. Finally, Kernodle & Katon Asset Management Group LLC raised its stake in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares during the last quarter. 11.28% of the stock is currently owned by institutional investors and hedge funds.

Novartis AG (NVS) traded up 0.12% during mid-day trading on Friday, hitting $84.97. The company had a trading volume of 990,062 shares. The firm’s 50 day moving average is $83.64 and its 200 day moving average is $78.07. The company has a market capitalization of $199.08 billion, a price-to-earnings ratio of 31.02 and a beta of 0.73. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90.

Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. During the same period last year, the firm earned $1.23 EPS. Novartis AG’s revenue for the quarter was down 1.8% compared to the same quarter last year. On average, equities research analysts predict that Novartis AG will post $4.75 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/05/novartis-ag-nvs-shares-bought-by-duncker-streett-co-inc.html.

NVS has been the topic of several research reports. Vetr lowered Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 target price on the stock. in a research note on Tuesday, April 25th. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research note on Thursday, June 22nd. Cowen and Company restated a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 18th. UBS AG restated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, May 30th. Finally, Zacks Investment Research lowered Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $81.71.

In related news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were bought at an average cost of $15.00 per share, with a total value of $4,000,005.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.01% of the stock is currently owned by company insiders.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.